

Finally, the comment stated that FDA's reporting burden estimate is too low because successful telephone contact typically requires multiple attempts. FDA disagrees with this

comment for two reasons: First, the burden of making multiple attempts to contact a potential survey respondent will fall on FDA, not on the potential respondent. Second, the burden

estimate already includes time to be spent by respondents to set up a subsequent interview.

FDA estimates the burden of this survey as follows:

#### ESTIMATED ANNUAL REPORTING BURDEN

Burden Element	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Part 1—Computer Assisted Telephone Interview (CATI)					
Respond to initial recruitment telephone call	1,231	1	1,231	0.2	246.2
Receive and read introductory letter, key term definitions	1,231	1	1,231	0.25	307.75
Obtain data to prepare for the telephone interview	1,231	1	1,231	0.35	430.85
Respond to telephone interview	1,231	1	1,231	0.5	615.50
Totals		1			1,600.3
Part 2—Onsite Cost Interview					
Receive initial recruitment telephone call	17	1	17	0.2	3.4
Receive and read introductory letter and materials	17	1	17	0.25	4.25
Obtain data to prepare for the site visit	17	1	17	0.5	8.5
Respond to questions during site visit	17	1	17	3.0	51.0
Followup questions	17	1	17	0.25	4.25
Total burden hours, onsite interviews					71.4

There are no capital costs or operating and maintenance costs associated with this collection of information.

The total burden hours for Part 1—CATI and Part 2—Onsite Cost Interview are 1,671.7.

The burden hour estimates are based on a pretest conducted with three focus groups.

Dated: July 30, 1997.

**William K. Hubbard,**

*Associate Commissioner for Policy Coordination.*

[FR Doc. 97-20754 Filed 8-6-97; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 97N-0317]

#### Agency Information Collection Activities; Submission for OMB Review; Comment Request

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

**DATES:** Submit written comments on the collection of information by September 8, 1997.

**ADDRESSES:** Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Desk Officer for FDA.

**FOR FURTHER INFORMATION CONTACT:** Margaret R. Wolff, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B-19, Rockville, MD 20857, 301-827-1223.

**SUPPLEMENTARY INFORMATION:** In compliance with section 3507 of the PRA (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance.

#### Interstate Shellfish Dealers Certificate—(OMB Control Number 0910-0021)—Reinstatement

Under 42 U.S.C. 243, FDA is required to cooperate with and aid State and local authorities in the enforcement of their health regulations and is authorized to assist States in the prevention and suppression of communicable diseases. Under this authority, FDA participates with State regulatory agencies, some foreign nations, and the molluscan shellfish

industry in the National Shellfish Sanitation Program (NSSP). The NSSP is a voluntary, cooperative program to promote the safety of molluscan shellfish by providing for the classification and patrol of shellfish growing waters and for the inspection and certification of shellfish processors. Each participating State and foreign nation monitors its molluscan shellfish processors and issues certificates for those that meet the State or foreign shellfish control authority's criteria. Each participating State and nation provides a certificate of its certified shellfish processors to FDA on Form FDA 3038, "Interstate Shellfish Dealer's Certificate." FDA uses this information to publish the "Interstate Certified Shellfish Shippers List," a monthly comprehensive listing of all molluscan shellfish processors certified under the cooperative program. If FDA did not collect the information necessary to compile this list, participating States would not be able to identify and keep out shellfish processed by uncertified processors in other States and foreign nations. Consequently, the NSSP would not be able to control the distribution of uncertified and possibly unsafe shellfish in interstate commerce, and its effectiveness would be nullified.

## ESTIMATED ANNUAL REPORTING BURDEN

Form No.	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
FDA 3038	33	70	2,310	.10	231

There are no capital costs or operating and maintenance costs associated with this collection.

This estimate is based on the number of certificates received in 1996.

Dated: July 31, 1997.

**William K. Hubbard,**  
Associate Commissioner for Policy  
Coordination.

[FR Doc. 97-20868 Filed 8-6-97; 8:45 am]

BILLING CODE 4160-01-F

information unless it displays a currently valid OMB control number.

Dated: July 31, 1997.

**William K. Hubbard,**  
Associate Commissioner for Policy  
Coordination.

[FR Doc. 97-20869 Filed 8-6-97; 8:45 am]

BILLING CODE 4160-01-F

**SUPPLEMENTARY INFORMATION:** In compliance with section 3507 of the PRA (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance.

**Notice of Participation—(21 CFR 12.45) (OMB Control Number 0910-0191—Reinstatement)**

Under part 12 (21 CFR part 12) regulations issued under sections 201-903 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321-393), any interested person may participate in a formal evidentiary hearing, either personally or through a representative by filing a notice of participation under § 12.45. Section 12.45 requires that any person filing a notice of participation state the person's specific interest in the proceedings, including the specific issues of fact about which the person desires to be heard. This section also requires that the notice include a statement that the person will present documentary evidence on testimony at the hearing and will comply with specific requirements in § 12.85 or, in the case of a hearing before a Public Board of Inquiry, in 21 CFR 13.25, concerning disclosure of data and information by participants. A participant's appearance can be struck by the presiding officer in accordance with § 12.45(e).

The information obtained is used by the presiding officer and other participants in a hearing to identify specific interests to be presented. This preliminary information serves to expedite the prehearing conference and commits participation.

The affected respondents are individuals or households, State or local governments, not-for-profit institutions and businesses or other for-profit groups and institutions.

FDA estimates the burden of this collection of information as follows:

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 97N-0143]

**Agency Information Collection Activities; Announcement of OMB Approval**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Citizen Petition" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

**FOR FURTHER INFORMATION CONTACT:** Margaret R. Wolff, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of April 28, 1997 (62 FR 22959), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). OMB has now approved the information collection and has assigned OMB control number 0910-0183. The approval expires on June 30, 2000. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 97N-0323]

**Agency Information Collection Activities; Submission for OMB Review; Comment Request**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

**DATES:** Submit written comments on the collection of information by September 8, 1997.

**ADDRESSES:** Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Desk Officer for FDA.

**FOR FURTHER INFORMATION CONTACT:** JonnaLynn P. Capezzuto, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B-19, Rockville, MD 20857, 301-827-4659.

## ESTIMATED ANNUAL REPORTING BURDEN

21 CFR Section	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
12.45	92	1	92	3	276

There are no capital costs or operating and maintenance costs associated with this collection of information.